168 related articles for article (PubMed ID: 38493688)
1. Targeting the "tumor microenvironment": RNA-binding proteins in the spotlight in colorectal cancer therapy.
Zhang Y; Zhang Y; Song J; Cheng X; Zhou C; Huang S; Zhao W; Zong Z; Yang L
Int Immunopharmacol; 2024 Apr; 131():111876. PubMed ID: 38493688
[TBL] [Abstract][Full Text] [Related]
2. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
[TBL] [Abstract][Full Text] [Related]
3. m5C regulator-mediated modification patterns and tumor microenvironment infiltration characterization in colorectal cancer: One step closer to precision medicine.
Chen B; Xi Y; Zhao J; Hong Y; Tian S; Zhai X; Chen Q; Ren X; Fan L; Xie X; Jiang C
Front Immunol; 2022; 13():1049435. PubMed ID: 36532062
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of RNA-binding proteins in human colorectal cancer.
Fan X; Liu L; Shi Y; Guo F; Wang H; Zhao X; Zhong D; Li G
World J Surg Oncol; 2020 Aug; 18(1):222. PubMed ID: 32828126
[TBL] [Abstract][Full Text] [Related]
5. Interaction between N
Yao J; Song Y; Yu X; Lin Z
Mol Med; 2023 Sep; 29(1):129. PubMed ID: 37737134
[TBL] [Abstract][Full Text] [Related]
6. Identification of RNA-Binding Proteins with Prognostic Prediction in Colorectal Cancer.
Bai XF; Liu JW
Biomed Res Int; 2021; 2021():7114445. PubMed ID: 34778456
[TBL] [Abstract][Full Text] [Related]
7. EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment.
Li C; Song J; Guo Z; Gong Y; Zhang T; Huang J; Cheng R; Yu X; Li Y; Chen L; Ma X; Sun Y; Wang Y; Xue L
Front Immunol; 2022; 13():857808. PubMed ID: 35432300
[TBL] [Abstract][Full Text] [Related]
8. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of an RBP gene signature for prognosis prediction in colorectal cancer based on WGCNA.
Cao L; Duan L; Zhang R; Yang W; Yang N; Huang W; Chen X; Wang N; Niu L; Zhou W; Chen J; Li Y; Zhang Y; Liu J; Fan D; Liu H
Hereditas; 2023 Mar; 160(1):10. PubMed ID: 36895014
[TBL] [Abstract][Full Text] [Related]
10. Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer.
Huang X; Ke K; Jin W; Zhu Q; Zhu Q; Mei R; Zhang R; Yu S; Shou L; Sun X; Feng J; Duan T; Mou Y; Xie T; Wu Q; Sui X
Front Immunol; 2022; 13():887048. PubMed ID: 35784334
[TBL] [Abstract][Full Text] [Related]
11. PROX1 interaction with α-SMA-rich cancer-associated fibroblasts facilitates colorectal cancer progression and correlates with poor clinical outcomes and therapeutic resistance.
Lai SW; Cheng YC; Kiu KT; Yen MH; Chen YW; Yadav VK; Yeh CT; Kuo KT; Chang TC
Aging (Albany NY); 2024 Jan; 16(2):1620-1639. PubMed ID: 38244581
[TBL] [Abstract][Full Text] [Related]
12. Follistatin-Like 3 Correlates With Lymph Node Metastasis and Serves as a Biomarker of Extracellular Matrix Remodeling in Colorectal Cancer.
Yang C; Cao F; Huang S; Zheng Y
Front Immunol; 2021; 12():717505. PubMed ID: 34335633
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment characterization in colorectal cancer to identify prognostic and immunotherapy genes signature.
Guo XW; Lei RE; Zhou QN; Zhang G; Hu BL; Liang YX
BMC Cancer; 2023 Aug; 23(1):773. PubMed ID: 37596528
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of colorectal cancer: A five-gene prognostic signature based on RNA-binding proteins.
Liang Q; Du X; Mao L; Wang G
Saudi J Gastroenterol; 2021; 27(4):223-233. PubMed ID: 34169901
[TBL] [Abstract][Full Text] [Related]
15. MYL9 expressed in cancer-associated fibroblasts regulate the immune microenvironment of colorectal cancer and promotes tumor progression in an autocrine manner.
Deng S; Cheng D; Wang J; Gu J; Xue Y; Jiang Z; Qin L; Mao F; Cao Y; Cai K
J Exp Clin Cancer Res; 2023 Nov; 42(1):294. PubMed ID: 37926835
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer.
Jiang T; Xing L; Zhao L; Ye Z; Yu D; Lin S
BMC Med Genomics; 2023 May; 16(1):105. PubMed ID: 37194014
[TBL] [Abstract][Full Text] [Related]
17. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.
Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
[TBL] [Abstract][Full Text] [Related]
18. NAV3 Is a Novel Prognostic Biomarker Affecting the Immune Status of the Tumor Microenvironment in Colorectal Cancer.
Li M; Wang Z; Dong S; Xu Y
J Immunol Res; 2022; 2022():8337048. PubMed ID: 35812247
[TBL] [Abstract][Full Text] [Related]
19. Small Extracellular Vesicles: Key Forces Mediating the Development and Metastasis of Colorectal Cancer.
Zhang W; Hu X; Jiang Z
Cells; 2022 May; 11(11):. PubMed ID: 35681475
[TBL] [Abstract][Full Text] [Related]
20. Involvement of parathyroid hormone-related peptide in the aggressive phenotype of colorectal cancer cells.
Novoa Díaz MB; Carriere PM; Martín MJ; Calvo N; Gentili C
World J Gastroenterol; 2021 Nov; 27(41):7025-7040. PubMed ID: 34887626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
